Eli Lilly launches insulin glargine biosimilar Rezvoglar®

Eli Lilly has launched its insulin glargine Rezvoglar®, biosimilar to Sanofi’s Lantus®, on the US market.  It will be offered at a 78% discount to Lantus®.  Rezvoglar® is the second insulin glargine biosimilar (following Viatris/Mylan’s Semglee®) to be supplied to the US.  Lilly received FDA approval for Rezvoglar® on 18 November 2022.